Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Return on Equity (2016 - 2025)

Cytokinetics (CYTK) has disclosed Return on Equity for 14 consecutive years, with 0.66% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity changed N/A to 0.66% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.66%, a N/A change, with the full-year FY2023 number at 2.12%, up 718.0% from a year prior.
  • Return on Equity was 0.66% for Q4 2025 at Cytokinetics, down from 0.69% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 5.55% in Q4 2022 to a low of 11.85% in Q3 2024.
  • A 5-year average of 0.14% and a median of 0.69% in 2025 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: plummeted -1320bps in 2024, then soared 1253bps in 2025.
  • Cytokinetics' Return on Equity stood at 0.82% in 2021, then surged by 774bps to 5.55% in 2022, then plummeted by -77bps to 1.27% in 2023, then tumbled by -1032bps to 11.85% in 2024, then surged by 106bps to 0.66% in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Return on Equity are 0.66% (Q4 2025), 0.69% (Q3 2025), and 1.41% (Q2 2025).